FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.


Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
21 Sep 2021
Historique:
received: 12 03 2021
accepted: 20 08 2021
entrez: 22 9 2021
pubmed: 23 9 2021
medline: 23 9 2021
Statut: epublish

Résumé

Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing

Identifiants

pubmed: 34548493
doi: 10.1038/s41523-021-00331-8
pii: 10.1038/s41523-021-00331-8
pmc: PMC8455671
doi:

Types de publication

Journal Article

Langues

eng

Pagination

125

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s).

Références

Ann Oncol. 2020 Mar;31(3):377-386
pubmed: 32067679
Clin Breast Cancer. 2013 Dec;13(6):421-432.e8
pubmed: 24267730
J Clin Oncol. 2016 Feb 10;34(5):419-26
pubmed: 26503204
J Clin Oncol. 2018 Jun 1;36(16):1556-1563
pubmed: 29664714
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Cancers (Basel). 2019 Dec 16;11(12):
pubmed: 31888289
Nat Genet. 2019 Oct;51(10):1450-1458
pubmed: 31570896
Nat Commun. 2018 Mar 1;9(1):896
pubmed: 29497091
PLoS One. 2015 Sep 30;10(9):e0138341
pubmed: 26421426
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Breast Cancer Res Treat. 2019 Nov;178(2):451-458
pubmed: 31422497
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):55-66
pubmed: 28361188
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Ann Oncol. 2016 Apr;27(4):619-24
pubmed: 26598545
Br J Cancer. 2017 Mar 14;116(6):726-730
pubmed: 28183140
J Clin Oncol. 2012 Aug 1;30(22):2718-24
pubmed: 22565002
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
JAMA Oncol. 2016 Oct 01;2(10):1310-1315
pubmed: 27532364
J Nucl Med. 2013 Nov;54(11):1862-8
pubmed: 24092940

Auteurs

Andrea Gombos (A)

Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium. andrea.gombos@bordet.be.
Université Libre de Bruxelles, Brussels, Belgium. andrea.gombos@bordet.be.

David Venet (D)

Université Libre de Bruxelles, Brussels, Belgium.
Breast Cancer Translational Research Laboratory, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.

Lieveke Ameye (L)

Statistical Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Peter Vuylsteke (P)

Medical Oncology, UCLouvain, CHU Namur Site Sainte-Elisabeth, Namur, Belgium.
University of Botswana, Private Bag UB 0022, Gabarone, Botswana.

Patrick Neven (P)

Multidisciplinary Breast Center and Department of Gynecology and Obstetrics, UZ Leuven, KU Leuven, Leuven, Belgium.

Vincent Richard (V)

Medical Oncology CHU Ambroise Paré, Mons, Belgium.

Francois P Duhoux (FP)

Medical Oncology Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Jean-Francois Laes (JF)

OncoDNA, Gosselies, Belgium.

Françoise Rothe (F)

Université Libre de Bruxelles, Brussels, Belgium.
Breast Cancer Translational Research Laboratory, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.

Christos Sotiriou (C)

Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
Université Libre de Bruxelles, Brussels, Belgium.
Breast Cancer Translational Research Laboratory, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.

Marianne Paesmans (M)

Statistical Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Ahmad Awada (A)

Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
Université Libre de Bruxelles, Brussels, Belgium.

Thomas Guiot (T)

Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium.

Patrick Flamen (P)

Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium.

Martine Piccart-Gebhart (M)

Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
Université Libre de Bruxelles, Brussels, Belgium.

Michail Ignatiadis (M)

Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
Université Libre de Bruxelles, Brussels, Belgium.

Géraldine Gebhart (G)

Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium.

Classifications MeSH